Partner with Us
Berkeley Lab is building on its strong legacy of innovation and partnerships by reaching out to researchers in the private and public sectors with a call for collaboration. Whatever the size of your idea or organization, from start-up to multinational, we invite you to explore partnership opportunities with us!
The mission of the Strategic Partnerships Office is to help potential partners and Lab researchers identify collaborative opportunities and form strategic partnerships. These partnerships enable access to the Lab’s expertise, capabilities and facilities as we work together to address the world’s most critical energy and environment challenges.
R&D Focus Areas
Featured Case Study
Showing an inspiring knack for innovation under pressure, the global scientific community has developed promising tests and treatments for COVID-19 in the span of just a few months. But moving medical technologies from conception to deployment at such an unprecedented rate comes with a multitude of hurdles, one of which is the obvious challenge of scale. How do companies turn a handful of prototypes or a few flasks of drug-secreting cells into a mass-produced product ready for market?
This is the primary focus for process engineer scientists at the Advanced Biofuels and Bioproducts Process Development Unit (ABPDU) at Lawrence Berkeley National Laboratory (Berkeley Lab). The ABPDU was founded to serve as a resource of equipment and expertise for companies or institutions that are using biological processes to generate exciting and potentially revolutionary products. Since opening their doors in 2012, the unit has collaborated with more than 62 groups to accelerate the development of sustainable biofuels, smart materials, innovative foods, and next-generation medicines.
Eager to apply their biomanufacturing know-how to the current crisis, ABPDU teams have been working during the shelter-in-place orders to help two companies scale-up production of new technologies that could aid in ending the pandemic.
Rapid, portable test kits using CRISPR
Although diagnostic testing for COVID-19 is becoming increasingly accessible, the test kits currently in use at hospitals, clinics, and walk-in centers around the world have many limitations. To detect the presence of coronavirus (SARS-CoV-2) from nasal and throat swabs, most of these kits have to be analyzed in centralized laboratories, with trained personnel and sophisticated equipment. Hoping to shift the paradigm, Argentina-based startup Caspr Biotech is developing a streamlined testing approach based on the increasingly powerful CRISPR gene editing system.
Cyclotron Road Applications for Cohort 2023 are Now Open
Application submission closes October 31, 2022
Optimizing SWAP Networks for Quantum Computing
August 4, 2022
New Public-Private Partnership to Upgrade Tool That Estimates Costs of Power Interruptions
News Release Media Relations (510) 486-5183 • July 27, 2022
National Energy Storage Summit